share_log

Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2

Benzinga Real-time News ·  Oct 7, 2022 08:41

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment